首页 > 最新文献

Clinical Medicine Insights-Reproductive Health最新文献

英文 中文
Combined first-trimester screening in northern Finland: experiences of the first ten years. 芬兰北部的联合孕早期筛查:前十年的经验。
Pub Date : 2014-07-30 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S14958
Anna Merilainen, Sini Peuhkurinen, Timppa Honkasalo, Paivi Laitinen, Hannaleena Kokkonen, Markku Ryynanen, Jaana Marttala

Objective: To evaluate the efficacy of first trimester combined screening for Down's syndrome in Northern Finland during the first 10 years of practice.

Methods: During 1 January 2002 to 31 December 2011, 47,896 women participated voluntarily in combined screening during first trimester. The risk cutoff was 1:250. The study period was divided into two time periods; 2002-2006 and 2007-2011.

Results: During the first half of the study period, the detection rate (DR) was 77.3% with a 4.9% false-positive rate (FPR). During the latter half, the DR was 77.1% with a 2.8% FPR.

Conclusions: An important issue is the number of invasive procedures needed to detect one case of Down's syndrome. The screening performance improved markedly in the latter five years period since the FPR lowered from 4.9% to 2.8% and the number of invasive procedures needed to detect one case of Down's syndrome lowered from 15 to 11.

目的:评价芬兰北部地区前10年妊娠早期联合筛查唐氏综合征的效果。方法:2002年1月1日至2011年12月31日期间,47,896名妇女自愿参加了妊娠早期联合筛查。风险临界值是1:250。研究阶段分为两个时间段;2002-2006年和2007-2011年。结果:前半期的检出率(DR)为77.3%,假阳性率(FPR)为4.9%。在后半期,DR为77.1%,FPR为2.8%。结论:一个重要的问题是需要多少侵入性手术才能发现一例唐氏综合征。在之后的五年里,筛查效果显著提高,因为FPR从4.9%降至2.8%,检测一例唐氏综合症所需的侵入性手术次数从15次降至11次。
{"title":"Combined first-trimester screening in northern Finland: experiences of the first ten years.","authors":"Anna Merilainen,&nbsp;Sini Peuhkurinen,&nbsp;Timppa Honkasalo,&nbsp;Paivi Laitinen,&nbsp;Hannaleena Kokkonen,&nbsp;Markku Ryynanen,&nbsp;Jaana Marttala","doi":"10.4137/CMRH.S14958","DOIUrl":"https://doi.org/10.4137/CMRH.S14958","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of first trimester combined screening for Down's syndrome in Northern Finland during the first 10 years of practice.</p><p><strong>Methods: </strong>During 1 January 2002 to 31 December 2011, 47,896 women participated voluntarily in combined screening during first trimester. The risk cutoff was 1:250. The study period was divided into two time periods; 2002-2006 and 2007-2011.</p><p><strong>Results: </strong>During the first half of the study period, the detection rate (DR) was 77.3% with a 4.9% false-positive rate (FPR). During the latter half, the DR was 77.1% with a 2.8% FPR.</p><p><strong>Conclusions: </strong>An important issue is the number of invasive procedures needed to detect one case of Down's syndrome. The screening performance improved markedly in the latter five years period since the FPR lowered from 4.9% to 2.8% and the number of invasive procedures needed to detect one case of Down's syndrome lowered from 15 to 11.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S14958","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32599575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Ketoconazole inhibits ovulation as a result of arrest of follicular steroidogenesis in the rat ovary. 酮康唑抑制大鼠卵巢卵泡类固醇生成的结果。
Pub Date : 2014-06-09 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S15887
Michael Gal, Joseph Orly

Objective: Ketoconazole (KCZ) is a known inhibitor of steroidogenic P450 enzymes in the adrenal cortex and the gonads. Previous studies examined the potential clinical use of KCZ for attenuation of ovarian response to gonadotropin treatments. This study aimed to use the superovuating rat model to explore the effect of KCZ on ovarian steroidogenesis, follicular function, and development toward ovulation.

Methods: Prepubertal rats were treated with equine chorionic gonadotropin (eCG)/human CG (hCG) resulting in multiple follicular development and ovulation. The effect of KCZ on this model was examined by administration of KCZ-gel formula and subsequent analyses of ovarian steroidogenesis, rate of ovulation, morphometric assessments of follicular parameters, and cell-specific steroidogenic maturation of the treated ovaries.

Results: When applied shortly before gonadotropin stimulation, KCZ markedly reduced ovarian progesterone, androstenedione, and estradiol levels down to 18.7, 36.5, and 19.0%, respectively (P < 0.001). A single KCZ-gel administration of 6, 12, and 24 mg/rat resulted in reduction of ovulated ova/ovary down to 8.6 ± 4.9, 5.1 ± 4.3, and 2.4 ± 3.2, respectively, as compared to 13.6 ± 4.4 ova found in the oviduct of control-gel-injected animals (P < 0.001). An alternative protocol made use of small KCZ doses injected in non-gel formula (5 mg/dose/8 hours), commenced with the eCG administration and terminated 24 hours later; this treatment readily inhibited the ovulation rates to 6.6 ± 6.6 as compared to 16.5 ± 4.1 ova/ovary in the control group (P < 0.01). By contrast, KCZ failed to inhibit ovulation if administered 24 hours after eCG injection. Anovulation by KCZ resulted from arrest of follicular development at the stage of 800-840 μm Graafian follicles as compared to 920 μm of peri-ovulatory follicles (OFs) observed in the control group, P = 0.029. In addition, absence of CYP11A1 expression was evident in the granulosa cell layers of the growth-arrested follicles, which also lacked mucified mature cumulus cell complexes.

Conclusion: These results suggest that KCZ-mediated inhibition of follicular maturation probably results from impaired steroidogenesis at early phase of follicular development toward ovulation. Hence, attenuation of folliculogenesis by KCZ may be harnessed to modulate gonadotropin-ovarian stimulation in fertility treatments.

目的:酮康唑(KCZ)是一种已知的肾上腺皮质和性腺中甾体原P450酶的抑制剂。先前的研究考察了KCZ在降低卵巢对促性腺激素治疗反应方面的潜在临床应用。本研究旨在通过超排卵大鼠模型,探讨KCZ对卵巢甾体生成、卵泡功能及排卵发育的影响。方法:用马绒毛膜促性腺激素(eCG)/人绒毛膜促性腺激素(hCG)治疗青春期前大鼠,诱导多卵泡发育和排卵。KCZ对该模型的影响是通过给药KCZ凝胶配方和随后的卵巢类固醇生成、排卵率、卵泡参数的形态计量学评估以及处理后卵巢细胞特异性类固醇生成成熟的分析来检测的。结果:在促性腺激素刺激前使用KCZ可显著降低卵巢孕酮、雄烯二酮和雌二醇水平,分别降至18.7%、36.5%和19.0% (P < 0.001)。单独给药6、12和24 mg的KCZ-gel可使排卵的卵子/卵巢分别减少到8.6±4.9、5.1±4.3和2.4±3.2个,而注射对照凝胶的动物的输卵管中有13.6±4.4个卵子(P < 0.001)。另一种方案是使用非凝胶配方注射小剂量KCZ (5mg /剂量/8小时),从eCG给药开始,并在24小时后终止;对照组的排卵率为16.5±4.1个(P < 0.01),对照组的排卵率为6.6±6.6个(P < 0.01)。相比之下,如果在心电图注射后24小时给药,KCZ没有抑制排卵。KCZ导致卵泡发育在800-840 μm的Graafian卵泡阶段停止,而对照组的排卵周卵泡(OFs)为920 μm, P = 0.029。此外,在生长受阻的卵泡的颗粒细胞层中明显缺乏CYP11A1表达,也缺乏粘液化的成熟积云细胞复合物。结论:这些结果表明,kcz介导的卵泡成熟抑制可能是由于卵泡发育早期激素生成受损所致。因此,在生育治疗中,KCZ对卵泡发生的抑制可能被用来调节促性腺激素-卵巢刺激。
{"title":"Ketoconazole inhibits ovulation as a result of arrest of follicular steroidogenesis in the rat ovary.","authors":"Michael Gal,&nbsp;Joseph Orly","doi":"10.4137/CMRH.S15887","DOIUrl":"https://doi.org/10.4137/CMRH.S15887","url":null,"abstract":"<p><strong>Objective: </strong>Ketoconazole (KCZ) is a known inhibitor of steroidogenic P450 enzymes in the adrenal cortex and the gonads. Previous studies examined the potential clinical use of KCZ for attenuation of ovarian response to gonadotropin treatments. This study aimed to use the superovuating rat model to explore the effect of KCZ on ovarian steroidogenesis, follicular function, and development toward ovulation.</p><p><strong>Methods: </strong>Prepubertal rats were treated with equine chorionic gonadotropin (eCG)/human CG (hCG) resulting in multiple follicular development and ovulation. The effect of KCZ on this model was examined by administration of KCZ-gel formula and subsequent analyses of ovarian steroidogenesis, rate of ovulation, morphometric assessments of follicular parameters, and cell-specific steroidogenic maturation of the treated ovaries.</p><p><strong>Results: </strong>When applied shortly before gonadotropin stimulation, KCZ markedly reduced ovarian progesterone, androstenedione, and estradiol levels down to 18.7, 36.5, and 19.0%, respectively (P < 0.001). A single KCZ-gel administration of 6, 12, and 24 mg/rat resulted in reduction of ovulated ova/ovary down to 8.6 ± 4.9, 5.1 ± 4.3, and 2.4 ± 3.2, respectively, as compared to 13.6 ± 4.4 ova found in the oviduct of control-gel-injected animals (P < 0.001). An alternative protocol made use of small KCZ doses injected in non-gel formula (5 mg/dose/8 hours), commenced with the eCG administration and terminated 24 hours later; this treatment readily inhibited the ovulation rates to 6.6 ± 6.6 as compared to 16.5 ± 4.1 ova/ovary in the control group (P < 0.01). By contrast, KCZ failed to inhibit ovulation if administered 24 hours after eCG injection. Anovulation by KCZ resulted from arrest of follicular development at the stage of 800-840 μm Graafian follicles as compared to 920 μm of peri-ovulatory follicles (OFs) observed in the control group, P = 0.029. In addition, absence of CYP11A1 expression was evident in the granulosa cell layers of the growth-arrested follicles, which also lacked mucified mature cumulus cell complexes.</p><p><strong>Conclusion: </strong>These results suggest that KCZ-mediated inhibition of follicular maturation probably results from impaired steroidogenesis at early phase of follicular development toward ovulation. Hence, attenuation of folliculogenesis by KCZ may be harnessed to modulate gonadotropin-ovarian stimulation in fertility treatments.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S15887","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32474348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment. 补充辅酶Q10和接受IVF-ICSI治疗的妇女的卵母细胞非整倍体。
Pub Date : 2014-06-08 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S14681
Yaakov Bentov, Thomas Hannam, Andrea Jurisicova, Navid Esfandiari, Robert F Casper

Background: The age-related reduction in live-birth rate is attributed to a high rate of aneuploidy and follicle depletion. We showed in an animal model that treatment with Coenzyme Q10 (CoQ10) markedly improved reproductive outcome. The aim of this study was to compare the post-meiotic oocyte aneuploidy rate in in vitro fertilization (IVF) and intra cytoplasmic sperm injection (ICSI) patients treated with CoQ10 or placebo.

Methods: We conducted a double blind placebo controlled randomized trial that included IVF-ICSI patients 35-43 years of age. The patients were treated with either 600 mg of CoQ10 or an equivalent number of placebo caps. We compared the post-meiotic aneuploidy rate using polar body biopsy (PBBX) and comparative genomic hybridization (CGH). According to the power calculation, 27 patients were needed for each arm.

Results: Owing to safety concerns regarding the effects of polar body biopsy on embryo quality and implantation, the study was terminated before reaching the target number of participants. A total of 39 patients were evaluated and randomized (17 CoQ10, 22 placebo), 27 were given the study medication (12 CoQ10, 15 placebo), and 24 completed an IVF-ICSI cycle including PBBX and embryo transfer (10 CoQ10, 14 placebo). Average age, base line follicle stimulating hormone (FSH), peak estradiol and progesterone serum level, as well as the total number of human menopausal gonadotropin (hMG) units-did not differ between the groups. The rate of aneuploidy was 46.5% in the CoQ10 group compared to 62.8% in the control. Clinical pregnancy rate was 33% for the CoQ10 group and 26.7% for the control group.

Conclusion: No significant differences in outcome were detected between the CoQ10 and placebo groups. However, the final study was underpowered to detect a difference in the rate of aneuploidy.

背景:与年龄相关的活产率降低归因于非整倍体和卵泡衰竭的高发生率。我们在动物模型中显示,用辅酶Q10 (CoQ10)治疗可显著改善生殖结果。本研究的目的是比较体外受精(IVF)和细胞质内精子注射(ICSI)患者使用辅酶q10或安慰剂治疗的减数分裂后卵母细胞非整倍体率。方法:我们进行了一项双盲安慰剂对照随机试验,包括35-43岁的IVF-ICSI患者。这些患者要么服用600毫克辅酶q10,要么服用等量的安慰剂。我们使用极体活检(PBBX)和比较基因组杂交(CGH)比较减数分裂后非整倍体率。根据功率计算,每组需要27例患者。结果:出于对极体活检对胚胎质量和着床影响的安全考虑,本研究在达到目标参与者人数之前终止。共有39例患者被评估和随机化(17例辅酶q10, 22例安慰剂),27例接受研究药物治疗(12例辅酶q10, 15例安慰剂),24例完成IVF-ICSI周期,包括PBBX和胚胎移植(10例辅酶q10, 14例安慰剂)。平均年龄,基线促卵泡激素(FSH),峰值雌二醇和孕酮血清水平,以及人类绝经期促性腺激素(hMG)单位的总数在两组之间没有差异。辅酶q10组的非整倍体率为46.5%,而对照组为62.8%。CoQ10组临床妊娠率为33%,对照组为26.7%。结论:辅酶q10组与安慰剂组的预后无显著差异。然而,最终的研究在检测非整倍体率的差异方面能力不足。
{"title":"Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment.","authors":"Yaakov Bentov,&nbsp;Thomas Hannam,&nbsp;Andrea Jurisicova,&nbsp;Navid Esfandiari,&nbsp;Robert F Casper","doi":"10.4137/CMRH.S14681","DOIUrl":"https://doi.org/10.4137/CMRH.S14681","url":null,"abstract":"<p><strong>Background: </strong>The age-related reduction in live-birth rate is attributed to a high rate of aneuploidy and follicle depletion. We showed in an animal model that treatment with Coenzyme Q10 (CoQ10) markedly improved reproductive outcome. The aim of this study was to compare the post-meiotic oocyte aneuploidy rate in in vitro fertilization (IVF) and intra cytoplasmic sperm injection (ICSI) patients treated with CoQ10 or placebo.</p><p><strong>Methods: </strong>We conducted a double blind placebo controlled randomized trial that included IVF-ICSI patients 35-43 years of age. The patients were treated with either 600 mg of CoQ10 or an equivalent number of placebo caps. We compared the post-meiotic aneuploidy rate using polar body biopsy (PBBX) and comparative genomic hybridization (CGH). According to the power calculation, 27 patients were needed for each arm.</p><p><strong>Results: </strong>Owing to safety concerns regarding the effects of polar body biopsy on embryo quality and implantation, the study was terminated before reaching the target number of participants. A total of 39 patients were evaluated and randomized (17 CoQ10, 22 placebo), 27 were given the study medication (12 CoQ10, 15 placebo), and 24 completed an IVF-ICSI cycle including PBBX and embryo transfer (10 CoQ10, 14 placebo). Average age, base line follicle stimulating hormone (FSH), peak estradiol and progesterone serum level, as well as the total number of human menopausal gonadotropin (hMG) units-did not differ between the groups. The rate of aneuploidy was 46.5% in the CoQ10 group compared to 62.8% in the control. Clinical pregnancy rate was 33% for the CoQ10 group and 26.7% for the control group.</p><p><strong>Conclusion: </strong>No significant differences in outcome were detected between the CoQ10 and placebo groups. However, the final study was underpowered to detect a difference in the rate of aneuploidy.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S14681","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32474347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 89
Management of Vaginal Atrophy: Implications from the REVIVE Survey. 阴道萎缩的处理:来自REVIVE调查的启示。
Pub Date : 2014-06-08 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S14498
Susan Wysocki, Sheryl Kingsberg, Michael Krychman

Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA.

外阴和阴道萎缩(VVA)是绝经后妇女常见的慢性进行性疾病。VVA的症状如性交困难、阴道干燥、刺激和瘙痒会对性功能和生活质量产生负面影响。REVIVE(绝经期阴道变化治疗方案的真实女性观点)调查评估了VVA的知识,并记录了与医疗保健提供者(HCPs)互动的态度和VVA的可用治疗方案。REVIVE调查确定了有VVA症状的妇女的需求未得到满足,例如对病情了解不足,尽管存在阴道症状,但与HCPs沟通不良,以及对现有VVA治疗的安全性、便利性和有效性的担忧。HCPs可以通过主动识别VVA患者并教育他们有关病情以及讨论VVA的治疗偏好和可用治疗方法来解决这些未满足的需求。
{"title":"Management of Vaginal Atrophy: Implications from the REVIVE Survey.","authors":"Susan Wysocki,&nbsp;Sheryl Kingsberg,&nbsp;Michael Krychman","doi":"10.4137/CMRH.S14498","DOIUrl":"https://doi.org/10.4137/CMRH.S14498","url":null,"abstract":"<p><p>Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey assessed knowledge about VVA and recorded attitudes about interactions with healthcare providers (HCPs) and available treatment options for VVA. The REVIVE survey identified unmet needs of women with VVA symptoms such as poor understanding of the condition, poor communication with HCPs despite the presence of vaginal symptoms, and concerns about the safety, convenience, and efficacy of available VVA treatments. HCPs can address these unmet needs by proactively identifying patients with VVA and educating them about the condition as well as discussing treatment preferences and available therapies for VVA. </p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S14498","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32474346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 68
Selective inhibition of steroidogenic enzymes by ketoconazole in rat ovary cells. 酮康唑对大鼠卵巢细胞甾体生成酶的选择性抑制作用。
Pub Date : 2014-02-17 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S14036
Michael Gal, Joseph Orly

Objective: Ketoconazole (KCZ) is an anti-fungal agent extensively used for clinical applications related to its inhibitory effects on adrenal and testicular steroidogenesis. Much less information is available on the effects of KCZ on synthesis of steroid hormones in the ovary. The present study aimed to characterize the in situ effects of KCZ on steroidogenic enzymes in primary rat ovary cells.

Methods: Following the induction of folliculogenesis in gonadotropin treated rats, freshly prepared ovarian cells were incubated in suspension for up to four hours while radiolabeled steroid substrates were added and time dependent generation of their metabolic products was analyzed by thin layer chromatography (TLC).

Results: KCZ inhibits the P450 steroidogenic enzymes in a selective and dose dependent manner, including cholesterol side-chain cleavage cytochrome P450 (CYP11A1/P450scc), the 17α-hydroxylase activity of CYP17A1/P450c17, and CYP19A1/P450arom, with IC50 values of 0.3, 1.8, and 0.3 μg/mL (0.56, 3.36, and 0.56 μM), respectively. Unaffected by KCZ, at 10 μg/mL, were the 17,20 lyase activity of CYP17A1, as well as five non-cytochrome steroidogenic enzymes including 3β-hydroxysteroid dehydrogenase-Δ(5-4) isomerase type 1 (3βHSD1), 5α-reductase, 20α-hydroxysteroid dehydrogenase (20α-HSD), 3α-hydroxysteroid dehydrogenase (3α-HSD), and 17β-hydroxysteroid dehydrogenase type 1 (17HSD1).

Conclusion: These findings map the effects of KCZ on the ovarian pathways of progestin, androgen, and estrogen synthesis. Hence, the drug may have a potential use as an acute and reversible modulator of ovarian steroidogenesis in pathological circumstances.

目的:酮康唑(Ketoconazole, KCZ)具有抑制肾上腺和睾丸甾体生成的作用,是一种广泛应用于临床的抗真菌药物。关于KCZ对卵巢内类固醇激素合成的影响的信息少得多。本研究旨在研究KCZ对大鼠卵巢原代细胞中甾体生成酶的原位影响。方法:促性腺激素诱导大鼠卵泡生成后,新鲜制备的卵巢细胞悬液孵育4小时,同时加入放射性标记的类固醇底物,薄层色谱(TLC)分析其代谢产物的时间依赖性生成。结果:KCZ对P450甾体生成酶(胆固醇侧链切割细胞色素P450 (CYP11A1/P450scc))、CYP17A1/P450c17和CYP19A1/P450arom的17α-羟化酶活性具有选择性和剂量依赖性,IC50值分别为0.3、1.8和0.3 μg/mL(0.56、3.36和0.56 μM)。在10 μg/mL浓度下,CYP17A1的17、20裂解酶活性以及3β-羟基类固醇脱氢酶-Δ(5-4)异构体酶1型(3β - hsd1)、5α-还原酶、20α-羟基类固醇脱氢酶(20α- hsd)、3α-羟基类固醇脱氢酶(3α-HSD)和17β-羟基类固醇脱氢酶1型(17HSD1)等5种非细胞色素体原酶活性均未受KCZ影响。结论:KCZ对卵巢黄体酮、雄激素和雌激素合成通路的影响。因此,在病理情况下,该药可能作为卵巢类固醇形成的急性和可逆调节剂有潜在的用途。
{"title":"Selective inhibition of steroidogenic enzymes by ketoconazole in rat ovary cells.","authors":"Michael Gal,&nbsp;Joseph Orly","doi":"10.4137/CMRH.S14036","DOIUrl":"https://doi.org/10.4137/CMRH.S14036","url":null,"abstract":"<p><strong>Objective: </strong>Ketoconazole (KCZ) is an anti-fungal agent extensively used for clinical applications related to its inhibitory effects on adrenal and testicular steroidogenesis. Much less information is available on the effects of KCZ on synthesis of steroid hormones in the ovary. The present study aimed to characterize the in situ effects of KCZ on steroidogenic enzymes in primary rat ovary cells.</p><p><strong>Methods: </strong>Following the induction of folliculogenesis in gonadotropin treated rats, freshly prepared ovarian cells were incubated in suspension for up to four hours while radiolabeled steroid substrates were added and time dependent generation of their metabolic products was analyzed by thin layer chromatography (TLC).</p><p><strong>Results: </strong>KCZ inhibits the P450 steroidogenic enzymes in a selective and dose dependent manner, including cholesterol side-chain cleavage cytochrome P450 (CYP11A1/P450scc), the 17α-hydroxylase activity of CYP17A1/P450c17, and CYP19A1/P450arom, with IC50 values of 0.3, 1.8, and 0.3 μg/mL (0.56, 3.36, and 0.56 μM), respectively. Unaffected by KCZ, at 10 μg/mL, were the 17,20 lyase activity of CYP17A1, as well as five non-cytochrome steroidogenic enzymes including 3β-hydroxysteroid dehydrogenase-Δ(5-4) isomerase type 1 (3βHSD1), 5α-reductase, 20α-hydroxysteroid dehydrogenase (20α-HSD), 3α-hydroxysteroid dehydrogenase (3α-HSD), and 17β-hydroxysteroid dehydrogenase type 1 (17HSD1).</p><p><strong>Conclusion: </strong>These findings map the effects of KCZ on the ovarian pathways of progestin, androgen, and estrogen synthesis. Hence, the drug may have a potential use as an acute and reversible modulator of ovarian steroidogenesis in pathological circumstances.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S14036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32327652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Educational effects of a tailored leaflet addressing drinking during pregnancy. 针对怀孕期间饮酒的量身定制传单的教育效果。
Pub Date : 2014-01-13 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S13461
Natsumi Toyama, Noriko Sudo

Objective: To examine the educational effects of a tailored leaflet on current drinking behavior, thoughts about drinking alcohol during pregnancy, and knowledge of fetal alcohol syndrome (FAS) among pregnant women.

Design: Intervention.

Participants: We recruited pregnant women who were participating in maternity classes held at five municipal health centers in Saitama Prefecture and Tokyo in Japan.

Methods: Questionnaires were administered before and after distribution of either a tailored or a non-tailored leaflet and again after the women delivered their babies.

Results: More women read the non-tailored leaflet than the tailored one; this was because they felt they could read the non-tailored leaflet immediately. As for educational effects, the tailored leaflet was not superior to the non-tailored one in changing the women's behavior, thoughts, or knowledge.

Conclusion: It is more important for health education leaflets to seem easy to read in terms of volume than to be tailored.

目的:探讨定制单张对孕妇当前饮酒行为、孕期饮酒想法和胎儿酒精综合征(FAS)知识的教育作用。设计:干预。参与者:我们招募了参加在日本埼玉县和东京的五个市级保健中心举办的产妇班的孕妇。方法:在分发定制或非定制传单之前和之后以及在妇女分娩后再次进行问卷调查。结果:阅读非定制宣传单的女性多于阅读定制宣传单的女性;这是因为他们觉得他们可以立即阅读非定制的传单。至于教育效果,量身定制的传单在改变女性的行为、思想或知识方面并不优于非量身定制的传单。结论:健康教育宣传单的易读性比针对性更重要。
{"title":"Educational effects of a tailored leaflet addressing drinking during pregnancy.","authors":"Natsumi Toyama,&nbsp;Noriko Sudo","doi":"10.4137/CMRH.S13461","DOIUrl":"https://doi.org/10.4137/CMRH.S13461","url":null,"abstract":"<p><strong>Objective: </strong>To examine the educational effects of a tailored leaflet on current drinking behavior, thoughts about drinking alcohol during pregnancy, and knowledge of fetal alcohol syndrome (FAS) among pregnant women.</p><p><strong>Design: </strong>Intervention.</p><p><strong>Participants: </strong>We recruited pregnant women who were participating in maternity classes held at five municipal health centers in Saitama Prefecture and Tokyo in Japan.</p><p><strong>Methods: </strong>Questionnaires were administered before and after distribution of either a tailored or a non-tailored leaflet and again after the women delivered their babies.</p><p><strong>Results: </strong>More women read the non-tailored leaflet than the tailored one; this was because they felt they could read the non-tailored leaflet immediately. As for educational effects, the tailored leaflet was not superior to the non-tailored one in changing the women's behavior, thoughts, or knowledge.</p><p><strong>Conclusion: </strong>It is more important for health education leaflets to seem easy to read in terms of volume than to be tailored.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S13461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32327651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A rare case of chronic ectopic pregnancy presenting as large hematosalpinx. 慢性异位妊娠表现为大输卵管血的罕见病例。
Pub Date : 2014-01-06 eCollection Date: 2014-01-01 DOI: 10.4137/CMRH.S13110
Madhavi Nacharaju, Venkata Sujatha Vellanki, Sarath Babu Gillellamudi, Vamsi Krishna Kotha, Abhinaya Alluri

Ectopic pregnancy is defined as implantation and subsequent development of an embryo outside the uterine lining. It has wide range of presentation from acute hemoperitoneum to chronic ectopic pregnancy. This is an unusual case of chronic ectopic pregnancy with large hematosalpinx without classical symptoms. A 22-year-old South Indian woman reported to the outpatient clinic with irregular spotting for a duration of 2 months which was not associated with pain. There was no preceding amenorrhea and previous menstrual cycles were regular. Clinically, the patient was hemodynamically stable but severely anemic. The abdomen was soft on palpation, cervical movements were not tender, and human chorionic gonadotropin was absent in the urine. Ultrasound revealed a complex adnexal mass. Magnetic resonance imaging (MRI) revealed a large hematosalpinx. Laparoscopic left salpingectomy was conducted and histopathology confirmed ectopic pregnancy. Ectopic pregnancy presents diagnostic dilemmas in the absence of classical symptoms. MRI and laparoscopy are important tools in such a diagnostic dilemma.

异位妊娠是指胚胎在子宫内膜外着床并随后发育。它有广泛的表现,从急性腹膜出血到慢性异位妊娠。这是一例罕见的慢性异位妊娠伴大量输卵管积血,无典型症状。一名22岁的南印度妇女到门诊报告了持续2个月的不规则斑点,与疼痛无关。既往无闭经,月经周期规律。临床上,患者血流动力学稳定,但严重贫血。腹部触诊柔软,宫颈运动不触痛,尿中未见人绒毛膜促性腺激素。超声显示一个复杂的附件肿块。磁共振成像(MRI)显示一个大的输卵管血。行腹腔镜左输卵管切除术,病理证实为异位妊娠。在没有经典症状的情况下,异位妊娠呈现诊断困境。MRI和腹腔镜检查在这种诊断困境中是重要的工具。
{"title":"A rare case of chronic ectopic pregnancy presenting as large hematosalpinx.","authors":"Madhavi Nacharaju,&nbsp;Venkata Sujatha Vellanki,&nbsp;Sarath Babu Gillellamudi,&nbsp;Vamsi Krishna Kotha,&nbsp;Abhinaya Alluri","doi":"10.4137/CMRH.S13110","DOIUrl":"https://doi.org/10.4137/CMRH.S13110","url":null,"abstract":"<p><p>Ectopic pregnancy is defined as implantation and subsequent development of an embryo outside the uterine lining. It has wide range of presentation from acute hemoperitoneum to chronic ectopic pregnancy. This is an unusual case of chronic ectopic pregnancy with large hematosalpinx without classical symptoms. A 22-year-old South Indian woman reported to the outpatient clinic with irregular spotting for a duration of 2 months which was not associated with pain. There was no preceding amenorrhea and previous menstrual cycles were regular. Clinically, the patient was hemodynamically stable but severely anemic. The abdomen was soft on palpation, cervical movements were not tender, and human chorionic gonadotropin was absent in the urine. Ultrasound revealed a complex adnexal mass. Magnetic resonance imaging (MRI) revealed a large hematosalpinx. Laparoscopic left salpingectomy was conducted and histopathology confirmed ectopic pregnancy. Ectopic pregnancy presents diagnostic dilemmas in the absence of classical symptoms. MRI and laparoscopy are important tools in such a diagnostic dilemma. </p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S13110","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32327650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Live birth from previously vitrified oocytes, after trophectoderm biopsy, revitrification, and transfer of a euploid blastocyst. 经滋养外胚层活检、再玻璃化和整倍体囊胚移植后,由先前玻璃化的卵母细胞活产。
Pub Date : 2013-09-10 DOI: 10.4137/CMRH.S11919
Jamie A Grifo, Brooke Hodes-Wertz, Hsiao Ling Lee, Esmeralda Ampeloquio, Melicia Clarke-Williams, Alexis Adler, Santiago Munné, Alan S Berkeley

Our objective is to describe a successful live birth from oocyte vitrification followed by thaw, fertilization, blastocyst culture, trophectoderm biopsy, vitrification, and subsequent thaw. Fifteen mature oocytes were frozen from a patient with uterine factor infertility. Thirteen oocytes survived the thaw, and five underwent trophectoderm biopsy and were refrozen. Three euploid embryos were obtained. A single euploid embryo was transferred in the second thaw cycle to a known recipient leading to the delivery of a normal male infant. This case report is proof of the concept that preimplantation screening and diagnosis is an option for fertility preservation patients.

我们的目标是描述一个成功的活产卵母细胞玻璃化,随后解冻,受精,囊胚培养,滋养外胚层活检,玻璃化,随后解冻。对一例子宫因素性不孕症患者的15个成熟卵母细胞进行冷冻。13个卵母细胞在解冻后存活,5个卵母细胞接受了滋养外胚层活检并重新冷冻。获得3个整倍体胚胎。在第二个解冻周期中,将一个单一的整倍体胚胎移植到一个已知的受体中,从而产生了一个正常的男婴。本病例报告证明了植入前筛查和诊断是保留生育能力患者的一种选择。
{"title":"Live birth from previously vitrified oocytes, after trophectoderm biopsy, revitrification, and transfer of a euploid blastocyst.","authors":"Jamie A Grifo,&nbsp;Brooke Hodes-Wertz,&nbsp;Hsiao Ling Lee,&nbsp;Esmeralda Ampeloquio,&nbsp;Melicia Clarke-Williams,&nbsp;Alexis Adler,&nbsp;Santiago Munné,&nbsp;Alan S Berkeley","doi":"10.4137/CMRH.S11919","DOIUrl":"https://doi.org/10.4137/CMRH.S11919","url":null,"abstract":"<p><p>Our objective is to describe a successful live birth from oocyte vitrification followed by thaw, fertilization, blastocyst culture, trophectoderm biopsy, vitrification, and subsequent thaw. Fifteen mature oocytes were frozen from a patient with uterine factor infertility. Thirteen oocytes survived the thaw, and five underwent trophectoderm biopsy and were refrozen. Three euploid embryos were obtained. A single euploid embryo was transferred in the second thaw cycle to a known recipient leading to the delivery of a normal male infant. This case report is proof of the concept that preimplantation screening and diagnosis is an option for fertility preservation patients. </p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S11919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32054757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Robotics in Gynecology: Why is this Technology Worth Pursuing? 妇科机器人:为什么这项技术值得追求?
Pub Date : 2013-07-24 DOI: 10.4137/CMRH.S10850
Rodrigo Ayala-Yáñez, Emilio José Olaya-Guzmán, Javier Haghenbeck-Altamirano

Robotic laparoscopy in gynecology, which started in 2005 when the Da Vinci Surgical System (Intuitive Surgical Inc) was approved by the US Food and Drug Administration for use in gynecologic procedures, represents today a modern, safe, and precise approach to pathology in this field. Since then, a great deal of experience has accumulated, and it has been shown that there is almost no gynecological surgery that cannot be approached with this technology, namely hysterectomy, myomectomy, sacrocolpopexia, and surgery for the treatment of endometriosis. Albeit no advantages have been observed over conventional laparoscopy and some open surgical procedures, robotics do seem to be advantageous in highly complicated procedures when extensive dissection and proper anatomy reestablishment is required, as in the case of oncologic surgery. There is no doubt that implementation of better logistics in finance, training, design, and application will exert a positive effect upon robotics expansion in gynecological medicine. Contrary to expectations, we estimate that a special impact is to be seen in emerging countries where novel technologies have resulted in benefits in the organization of health care systems.

2005年,达芬奇手术系统(Intuitive Surgical Inc)被美国食品和药物管理局批准用于妇科手术时,机器人腹腔镜在妇科领域的应用开始了,代表了今天该领域现代、安全、精确的病理方法。此后,积累了大量的经验,已经证明,几乎没有妇科手术不能采用这种技术,即子宫切除术、子宫肌瘤切除术、骶colpopexia、手术治疗子宫内膜异位症。虽然没有观察到比传统腹腔镜和一些开放式手术更有优势,但在高度复杂的手术中,当需要广泛的解剖和适当的解剖重建时,机器人技术似乎是有优势的,比如在肿瘤手术中。毫无疑问,在财务、培训、设计和应用等方面实施更好的物流,将对机器人技术在妇科医学领域的推广产生积极的影响。与预期相反,我们估计在新兴国家将会看到一种特殊的影响,在那里,新技术已经在卫生保健系统的组织中产生了好处。
{"title":"Robotics in Gynecology: Why is this Technology Worth Pursuing?","authors":"Rodrigo Ayala-Yáñez,&nbsp;Emilio José Olaya-Guzmán,&nbsp;Javier Haghenbeck-Altamirano","doi":"10.4137/CMRH.S10850","DOIUrl":"https://doi.org/10.4137/CMRH.S10850","url":null,"abstract":"<p><p>Robotic laparoscopy in gynecology, which started in 2005 when the Da Vinci Surgical System (Intuitive Surgical Inc) was approved by the US Food and Drug Administration for use in gynecologic procedures, represents today a modern, safe, and precise approach to pathology in this field. Since then, a great deal of experience has accumulated, and it has been shown that there is almost no gynecological surgery that cannot be approached with this technology, namely hysterectomy, myomectomy, sacrocolpopexia, and surgery for the treatment of endometriosis. Albeit no advantages have been observed over conventional laparoscopy and some open surgical procedures, robotics do seem to be advantageous in highly complicated procedures when extensive dissection and proper anatomy reestablishment is required, as in the case of oncologic surgery. There is no doubt that implementation of better logistics in finance, training, design, and application will exert a positive effect upon robotics expansion in gynecological medicine. Contrary to expectations, we estimate that a special impact is to be seen in emerging countries where novel technologies have resulted in benefits in the organization of health care systems. </p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S10850","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32054756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Fertility preservation options after gonadotoxic chemotherapy. 促性腺毒素化疗后的生育能力保存选择。
Pub Date : 2013-04-25 DOI: 10.4137/CMRH.S10848
Jordana Hadassah Hyman, Togas Tulandi

Chemotherapy has the potential to deplete and destroy a woman's reproductive potential. Although many oncologists are referring women for fertility preservation before chemotherapy, in many cases there is limited time for fertility preservation. This review provides an overview of the impact of cancer and chemotherapy on the ovarian reserve, a summary of methods of fertility preservation prior to chemotherapy, and current knowledge of fertility preservation techniques after gonadotoxic chemotherapy.

化疗有可能耗尽和破坏女性的生殖潜能。尽管许多肿瘤学家推荐女性在化疗前进行生育能力保存,但在许多情况下,生育能力保存的时间有限。本文综述了癌症和化疗对卵巢储备的影响,化疗前保留生育能力的方法,以及促性腺毒素化疗后保留生育能力技术的最新知识。
{"title":"Fertility preservation options after gonadotoxic chemotherapy.","authors":"Jordana Hadassah Hyman,&nbsp;Togas Tulandi","doi":"10.4137/CMRH.S10848","DOIUrl":"https://doi.org/10.4137/CMRH.S10848","url":null,"abstract":"<p><p>Chemotherapy has the potential to deplete and destroy a woman's reproductive potential. Although many oncologists are referring women for fertility preservation before chemotherapy, in many cases there is limited time for fertility preservation. This review provides an overview of the impact of cancer and chemotherapy on the ovarian reserve, a summary of methods of fertility preservation prior to chemotherapy, and current knowledge of fertility preservation techniques after gonadotoxic chemotherapy. </p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S10848","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32054755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
期刊
Clinical Medicine Insights-Reproductive Health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1